Heatwurx Inc.
PCSA- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
Follow PCSA
Alert me
Heatwurx Inc. (PCSA) Return on invested capital
Heatwurx Inc.'s return on invested capital over the twelve months to 30 September 2026 was 0.00%, up 21694.3 percentage points from fiscal 2025 (−21,694.3%). Over the past ten years it has ranged from −21,694.3% (fiscal 2025) to 0.00% (fiscal 2017) — the current reading is the lowest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −21,694.3% | (20,202.54) |
| FY2024 | −1,491.8% | 1,038.50 |
| FY2023 | −2,530.3% | (1,221.13) |
| FY2022 | −1,309.2% | (1,224.77) |
| FY2021 | −84.4% | 40.62 |
| FY2020 | −125.0% | (95.26) |
| FY2019 | −29.7% | 4.79 |
| FY2018 | −34.5% | (34.53) |
| FY2017 | 0.00% | 682.35 |
| FY2016 | −682.4% | (682.35) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NIKI Niki BioSolutions, Inc. compare | 0.00% |
| PULM Pulmatrix, Inc. compare | 0.00% |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | 0.00% |
| PCSA Heatwurx Inc. | 0.00% |
| CANF Can-Fite Biopharma Ltd compare | 0.00% |
| LTRN Lantern Pharma Inc. compare | 0.00% |
| SKYE Skye Bioscience, Inc. compare | 0.00% |
| JAGX Jaguar Animal Health, Inc. compare | −117.8% |
| CDIO Cardio Diagnostics Holdings, Inc. compare | −228.0% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)